Introduction
============

According to the latest data, lung cancer is the most common cancer worldwide and a leading cause of tumor-related mortality ([@b1-ijo-53-01-0073],[@b2-ijo-53-01-0073]). Lung cancer causes almost 1.4 million mortalities each year all over the world ([@b3-ijo-53-01-0073],[@b4-ijo-53-01-0073]). According to histological type, lung cancer is divided into two categories: Small-cell lung cancer (SCLC) and non-SCLC (NSCLC). NSCLC makes up 80--85% of all lung cancer cases ([@b5-ijo-53-01-0073]). The majority of the newly diagnosed NSCLC cases are at an advanced stage, with a low 5-year survival rate ([@b6-ijo-53-01-0073]). Hence, it is worthwhile to investigate the possible molecular mechanisms involved in NSCLC tumorigenesis and progression.

HOXA1, also known as BSAS, HOX1 or HOX1F, serves vital roles in multiple cancer types, including cervical, breast and esophageal cancer ([@b7-ijo-53-01-0073]--[@b9-ijo-53-01-0073]). HOXA1 is involved in the proliferation, migration and invasion of different cancer types, including esophageal cancer ([@b9-ijo-53-01-0073]), prostate cancer ([@b10-ijo-53-01-0073]) and NSCLC ([@b11-ijo-53-01-0073]). Zhan *et al* ([@b11-ijo-53-01-0073]) found that HOXA1 could act as the direct target of let-7c in NSCLC, and let-7c could inhibit the proliferation and tumorigenesis of NSCLC cells via partial targeting of HOXA1. Li *et al* ([@b9-ijo-53-01-0073]) found that the high expression of miR-30b could downregulate HOXA1 to inhibit the growth, migration and invasion of esophageal cancer cells. Several studies have shown the clinical role of HOXA1 in NSCLC. For example, Zha *et al* ([@b12-ijo-53-01-0073]) found that HOXA1 was overexpressed in hepatocellular carcinoma (HCC), and high HOXA1 expression was positively associated with the T classification, N classification, distant metastasis and the clinical stage of HCC patients. Additionally, the overexpression of HOXA1 associated with a shorter overall survival time. Yuan *et al* ([@b13-ijo-53-01-0073]) found that HOXA1 expression was positively associated with the development and clinical prognosis of gastric cancer. These findings suggest that HOXA1 could act as a novel prognostic biomarker in gastric cancer.

The present study sought to investigate the expression of HOXA1 in NSCLC and normal lung tissue based on reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Furthermore, The Cancer Genome Atlas (TCGA), Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA) and Multi Experiment Matrix (MEM) databases were used to assess the expression and the clinical role of HOXA1 in NSCLC. Bioinformatic analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), network and protein-protein interaction (PPI) analyses, were implemented to investigate the potential functions, pathways and networks of the co-expressed genes ([@b14-ijo-53-01-0073]--[@b16-ijo-53-01-0073]). Additionally, 12 miRNA target prediction algorithms were applied to predict the potential miRNAs targeting HOXA1.

Materials and methods
=====================

RT-qPCR
-------

A total of 53 NSCLC patients, including 31 lung adenocarcinoma (LUAD) patients and 22 lung squamous cell carcinoma (LUSC) patients, were enrolled from the Department of Pathology, First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, China). All 53 samples were randomly collected from patients undergoing surgical resection without treatment. All methods were applied according to the relevant guidelines. The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved the experimental protocols, and all patients provided written informed consent forms for the use of their tissues in this study. Total RNA was extracted via TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and a PCR amplification kit (Omega, Solarbio Biotechnologies, Inc., Shanghai, China) was used. The RNA was reverse-transcribed into cDNA using Roche cDNA Synthesis kit (Roche Diagnostics, Shanghai, China), based on the manufacturer\'s protocols. qPCR was performed using ABI 7500 prepstation (Applied Biosystems; Thermo Fisher Scientific, Inc.), and the SYBR^®^-Green PCR Master mix (GeneCore Biotechnologies, Inc., Shanghai, China). PCR was performed at 95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec and 60°C for 1 min for 40 cycles. The specific primers were as follows: HOXA1 forward, 5′-CGGCTTCCTGTGCTAAGTCT-3′ and reverse, 5′-TAGCCCAGCCAAATACACGG-3′; and GAPDH (internal control) forward, 5-′TGCACCACCAACTGCTTA-3′ and reverse, 5′-GGATGCAGGGATGATGTTC-3′. The results were normalized to the GAPDH expression and calculated based on the 2^−ΔΔCq^ method ([@b17-ijo-53-01-0073],[@b18-ijo-53-01-0073]).

Validation of the expression of HOXA1 in NSCLC
----------------------------------------------

TCGA (<http://cancergenome.nih.gov/>) has collected comprehensive molecular profiles, including gene expression, microRNA expression, protein expression and DNA methylation, for \>30 types of human tumors ([@b19-ijo-53-01-0073]--[@b21-ijo-53-01-0073]). TCGA also has information about complex clinical parameters. In the present study, the RNA-Seq data for patients with NSCLC, which were from the Illumina HiSeq RNA-Seq platform (Illumina, Inc., San Diego, CA, USA), contained 535 LUAD cases and 502 LUSC cases up to July 1, 2017 ([@b21-ijo-53-01-0073]). The expression data of HOXA1 are reported in reads per million, and the HOXA1 expression level was normalized by the R language package DESeq for further analysis. Student\'s t-test (SPSS Inc., Chicago, IL, USA) was used to compare differential expression of HOXA1 between NSCLC and normal lung tissues. Additionally, the potential associations between HOXA1 and the clinicopathological parameters in NSCLC were identified via the original TCGA database. The receiver operating characteristic (ROC) curve was derived to evaluate the diagnostic value of HOXA1. Oncomine (<https://www.oncomine.org/>) and GEPIA (<http://gepia.cancer-pku.cn/>) were applied to verify the HOXA1 expression in NSCLC ([@b22-ijo-53-01-0073],[@b23-ijo-53-01-0073]).

Potential functions and pathways associated with HOXA1
------------------------------------------------------

To further investigate the genes co-expressed with HOXA1, MEM (<http://biit.cs.ut.ee/mem/index.cgi>), GEPIA and cBioPortal (<http://www.cbioportal.org/>) were used. The Venn diagrams (<http://bioinformatics.psb.ugent.be/webtools/Venn/>) were used to identify and compare the overlaps. Next, bioinformatic analyses, including GO, KEGG and network analyses, were utilized to investigate the potential functions, pathways and networks of these overlapping genes as previously described ([@b24-ijo-53-01-0073]). In this process, the Database for Annotation, Visualization and Integrated Discovery (<http://david.abcc.ncifcrf.gov/>) was used for GO and KEGG analyses. Biological process, cellular component and molecular function were derived separately via GO analysis. A functional network was constructed through Cytoscape (version 2.8; <http://cytoscape.org>).

Construction of PPI network
---------------------------

The interaction pairs of the co-expressed genes were researched through the Search Tool for the Retrieval of Interacting Genes (STRING; version 9.0; <http://string-db.org>) ([@b25-ijo-53-01-0073]). The STRING database aims to supply a global perspective for as many organisms as feasible. Known and predicted associations are integrated and scored. A combined score over 0.4 was chosen to construct the PPI network.

Prediction of targeting miRNAs
------------------------------

A total of 12 target prediction algorithms were used for predicting the potential miRNAs targeting HOXA1: miRWalk (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>), DIANA microT v4 (<http://diana.imis.athena-innovation.gr/>), miRanda (<http://www.microrna.org>), mirBridge (<http://mirsystem.cgm.ntu.edu.tw/>), miRDB (<http://www.mirdb.org/>), miRMap (<http://mirmap.ezlab.org/>), miRNAMap (<http://mirnamap.mbc.nctu.edu.tw/>), Pictar2 (<https://www.mdc-berlin.de/>), PITA (<https://genie.weizmann.ac.il/>), RNA22 (<https://cm.jefferson.edu/>) RNAhybrid (<https://bibiserv.cebitec.uni-bielefeld.de/>) and TargetScan (<http://www.targetscan.org/>). Candidate miRNAs were identified based on Venn diagrams.

Statistical analysis
--------------------

All the original data from TCGA were log2-transformed. The mean ± standard deviation was calculated by SPSS 22.0 (IBM Corp., Armonk, NY, USA) to measure the HOXA1 expression level. Student\'s t-test was used to compare the differential expression of HOXA1 between NSCLC and normal lung tissues, as well as for the associations between HOXA1 expression and the clinicopathological parameters. One-way analysis of variance was applied to compare different subgroups. The Mann-Whitney U test or Kruskal-Wallis H test was utilized for non-normally distributed variables. The associations between HOXA1 expression and miRNA expression were assessed by Spearman\'s correlation. Mining for co-expressed genes across hundreds of datasets was performed through novel rank aggregation and visualization methods. Two-sided P-values of \<0.05 were identified to indicate statistical significance.

Results
=======

Clinical value of HOXA1 expression in NSCLC
-------------------------------------------

In the present study, HOXA1 mRNA was overexpressed in NSCLC compared with that in normal lung tissues (P=0.011; [Fig. 1A](#f1-ijo-53-01-0073){ref-type="fig"}). The associations between the expression of HOXA1 and different clinicopathological parameters were further investigated. HOXA1 expression was positively associated with advanced (stage III--IV) TNM, Tumor-Node-Metastasis (TNM) classification of malignant tumors ([@b26-ijo-53-01-0073]) and presence of lymph node metastasis (LNM) (both P\<0.001; [Fig. 1B](#f1-ijo-53-01-0073){ref-type="fig"} and C). No significant association was found between HOXA1 mRNA expression and any other clinicopathological parameter, including sex, tumor size and vascular invasion ([Table I](#tI-ijo-53-01-0073){ref-type="table"}). In addition, the diagnostic value of the HOXA1 level in NSCLC was assessed by ROC curve, and the area under the curve (AUC) of HOXA1 was 0.656 \[95% confidence interval (CI), 0.552--0.761; P=0.005; [Fig. 1D](#f1-ijo-53-01-0073){ref-type="fig"}). The expression of HOXA1 was also compared between LUAD and LUSC. The results were similar to those of NSCLC: HOXA1 was upregulated in LUSC (P=0.012; [Fig. 2A](#f2-ijo-53-01-0073){ref-type="fig"}), and HOXA1 expression was positively associated with the presence of LNM and an advanced TNM stage (III-IV, both P\<0.05) in LUAD and LUSC ([Fig. 2B--2E](#f2-ijo-53-01-0073){ref-type="fig"}; [Tables II](#tII-ijo-53-01-0073){ref-type="table"} and [III](#tIII-ijo-53-01-0073){ref-type="table"}). A moderate diagnostic value of the HOXA1 level was also found in LUAD (0.625; 95% CI, 0.502--0.748; P=0.057; [Fig. 2F](#f2-ijo-53-01-0073){ref-type="fig"}), although this was not significant, and in LUSC (0.700; 95% CI, 0.566--0.834; P=0.007; [Fig. 2G](#f2-ijo-53-01-0073){ref-type="fig"}). Comparison of HOXA1 expression between LUAD and LUSC tissues showed higher expression of HOXA1 in LUSC than LUAD.

To further research the differential expression of HOXA1 between NSCLC and non-cancerous lung tissues, original patient data was obtained from TCGA. Two NSCLC cohorts, which comprised i) 535 LUAD cases and 59 normal lung cases, and ii) 502 LUSC cases and 49 normal lung cases, were extracted. As a result, increased expression of HOXA1 was observed in LUAD and LUSC compared with that in normal lung tissues (both P\<0.05; [Fig. 3A](#f3-ijo-53-01-0073){ref-type="fig"} and B). Regarding the clinicopathological parameters, no statistical significance was reached based on the TCGA database ([Tables IV](#tIV-ijo-53-01-0073){ref-type="table"} and [V](#tV-ijo-53-01-0073){ref-type="table"}). The AUC of HOXA1 was 0.548 (95% CI, 0.498--0.599; P=0.002) for LUAD and 0.957 (95% CI, 0.940--0.974; P\<0.001) for LUSC based on TCGA, which indicated a high diagnostic value of the HOXA1 level in LUSC ([Fig. 3C and D](#f3-ijo-53-01-0073){ref-type="fig"}). With regard to overall survival, no statistical significance was determined; a trend was observed in which low HOXA1 expression was associated with an increased survival time (97.11±11.49 months) compared with high HOXA1 expression (75.15±9.68 months) (P=0.098; [Fig. 3E](#f3-ijo-53-01-0073){ref-type="fig"}) in LUAD, and the opposite trend was noted in LUSC (P=0.795; [Fig. 3F](#f3-ijo-53-01-0073){ref-type="fig"}), indicating that high HOXA1 expression may be associated with increased survival time of NSCLC patients.

A total of 11 datasets \[Hou Lung, Wachi Lung, Beer Lung, Stearman Lung, Garber Lung, Landi Lung, Bhattacharjee Lung, Su Lung, Talbot Lung, Selamat Lung and Okayama Lung ([@b22-ijo-53-01-0073])\] in Oncomine were used to validate the HOXA1 expression. Bhattacharjee Lung showed an opposite trend to all other datasets, as HOXA1 expression was downregulated compared with that in the normal lung. The results from the other 10 datasets were consistent with the present RT-qPCR and TCGA findings ([Fig. 4A and B](#f4-ijo-53-01-0073){ref-type="fig"}). GEPIA was used to further confirm the high expression of HOXA1 in LUAD and LUSC compared with that in the non-cancerous lung tissues ([Fig. 4C and D](#f4-ijo-53-01-0073){ref-type="fig"}).

Potential pathways associated with HOXA1
----------------------------------------

Based on GEPIA, TCGA and MEM, 1,264 overlapping co-expressed genes were selected ([Fig. 5](#f5-ijo-53-01-0073){ref-type="fig"}) for GO and KEGG pathway analyses. The strongly enriched GO functional terms were \'dGTP metabolic process\', \'network-forming collagen trimer\' and \'centromeric DNA binding\' ([Fig. 6](#f6-ijo-53-01-0073){ref-type="fig"}; [Table VI](#tVI-ijo-53-01-0073){ref-type="table"}). The KEGG pathway most strongly associated with the HOXA1 co-expressed genes was \'the p53 signaling pathway\' ([Table VII](#tVII-ijo-53-01-0073){ref-type="table"}). Altogether, the GO and KEGG pathway analyses indicated that HOXA1 may be associated with the biological mechanism of NSCLC.

A PPI network was constructed via STRING online, and a total of 3,250 PPI pairs with a combined score of \>0.4 were noted. The map of the PPI network that involved 908 PPI pairs was chosen for further analysis, and its connectivity degree was \>30 ([Fig. 7](#f7-ijo-53-01-0073){ref-type="fig"}). Trifunctional purine biosynthetic protein adenosine-3 (GART; degree=71) had the highest degree and most interactions, according to the PPI network.

A total of 17 genes (ZMAT3, CYCS, CHEK1, CDK6, SFN, SESN3, CCNB1, CCNE1, TP53I3, CDKN2A, CCNB2, CCND2, SERPINB5, DDB2, PERP, IGFBP3 and GADD45A) associated with the p53 signaling pathway were flagged by KEGG pathway analysis, and 4 genes (CDKN2A, RAD51, CHEK1 and GART) had a degree of connectivity of \>50 in the PPI network. The genes shared in common by these two lists were cyclin-dependent kinase inhibitor 2A (CDKN2A) and checkpoint kinase 1 (CHEK1). The expression of the two genes in the original TCGA data was investigated and it was found that each was highly expressed in LUAD and LUSC compared with that in normal lung tissues (both P\<0.001; [Fig. 8A--D](#f8-ijo-53-01-0073){ref-type="fig"}). Based on these results, we hypothesized that HOXA1 serves a vital role in NSCLC by co-expressing with CDKN2A and CHEK1.

Prediction of target miRNAs
---------------------------

In the present study, 12 target prediction algorithms were used to predict the potential miRNAs that targeted HOXA1. The miRNAs predicted by \>10 algorithms were selected as the final candidate miRNAs. A total of 3 miRNAs (miR-181b-5p, miR-28-5p, miR-181d-5p) targeting HOXA1 were predicted by the 10 algorithms. Based on TCGA, miR-181b, miR-28 and miR-181d levels were found to be significantly upregulated in LUAD compared with those in non-cancerous lung tissues (all P\<0.05; [Fig. 9A--C](#f9-ijo-53-01-0073){ref-type="fig"}). miR-181b and miR-181d levels were found to be significantly downregulated in LUSC, whereas miR-28 level was found to exhibit no significant difference in LUSC and normal lung tissues ([Fig. 9D--F](#f9-ijo-53-01-0073){ref-type="fig"}). Furthermore, the correlation between HOXA1 and these three miRNAs in NSCLC was compared using Spearman-test based on TCGA, and it was found that HOXA1 mRNA level was inversely correlated with miR-181b and miR-181d in both LUAD and LUSC (both P\<0.05; [Table VIII](#tVIII-ijo-53-01-0073){ref-type="table"}). However, miR-28 level was inversely correlated with HOXA1 mRNA level in LUAD (r=−0.010, P=0.827) and positively correlated in LUSC (r=0.057, P=0.216) ([Table VIII](#tVIII-ijo-53-01-0073){ref-type="table"}). Since miR-181b and miR-181d expression was downregulated in LUSC tissues and inversely correlated with HOXA1 expression, we speculate that HOXA1 may be the direct target of miR-181b-5p or miR-181d-5p in LUSC, and may serve a significant role in NSCLC by regulating various pathways, particularly the p53 signaling pathway. However, the detailed mechanism should be verified by functional experiments.

Discussion
==========

In the present study, RT-qPCR, TCGA, MEM, Oncomine and GEPIA were used to investigate the expression, clinical significance and possible functions or pathways of HOXA1 in NSCLC. It was found that HOXA1 was overexpressed in NSCLC based on the RT-qPCR, TCGA and GEPIA data. The ROC curve was utilized to evaluate the association between HOXA1 expression and diagnostic value, and the AUC of HOXA1 confirmed the moderate diagnostic value of HOXA1 in NSCLC. HOXA1 was confirmed as a tumorigenic gene, and high HOXA1 expression was associated with TNM stage and LNM. According to GO and KEGG analyses, the strongly enriched GO functional terms were \'dGTP metabolic process\', \'network-forming collagen trimer\' and \'centromeric DNA binding\', and the HOXA1 co-expressed genes were significantly associated with \'the p53 signaling pathway\'.

Several studies have investigated the effect of HOXA1 in NSCLC. Abe *et al* ([@b27-ijo-53-01-0073]) detected the expression levels of 39 HOX genes in 41 human NSCLC and normal lung tissues by RT-qPCR, and found that HOXA1 was highly expressed in NSCLC tissues and was upregulated in LUSC compared with that in LUAD. Similarly, the present study quantified the HOXA1 expression level in 53 NSCLC tissues and 53 normal lung tissues and found similar results on HOXA1 expression. Additionally, these expression findings were verified via other databases and the molecular mechanisms of HOXA1 action were predicted by GO and KEGG analyses. Abe *et al* ([@b27-ijo-53-01-0073]) hypothesized that HOX genes are involved in the histologically aberrant diversity, which would explain the different HOXA1 expression in LUAD and LUSC. Zhan *et al* ([@b11-ijo-53-01-0073]) found that HOXA1 could act as the direct target of let-7c in NSCLC, and that let-7c could inhibit the proliferation and tumorigenesis of NSCLC cells via partial targeting of HOXA1. The present study found that miR-181b and miR-181d were downregulated in LUSC tissues and that HOXA1 mRNA expression was inversely correlated with miR-181b and miR-181d levels based on TCGA. We speculate that HOXA1 may be the direct target of miR-181b-5p or miR-181d-5p in LUSC and that it may serve a significant role in NSCLC in combination with these miRNAs. However, the detailed mechanism of its activity should be verified by functional experiments.

Based on KEGG analysis, the p53 signaling pathway was the most strongly enriched pathway term. The p53 signaling pathway could serve a vital role in NSCLC, but no studies on HOXA1 and p53 signaling could be found in the global literature. Liu *et al* ([@b28-ijo-53-01-0073]) found that p53 was the most commonly mutated gene in NSCLC, being mutated in 45--70% of LUAD samples and 60--80% of LUSC samples. Normally, p53 is located in the cytoplasm, but it translocates to the nucleus following phosphorylation by various kinases upon cellular stress ([@b29-ijo-53-01-0073]). Phosphorylated nuclear p53 binds to different proteins to stimulate apoptosis ([@b30-ijo-53-01-0073]--[@b32-ijo-53-01-0073]). In addition to its effect on apoptosis, several studies have demonstrated the effect of p53 signaling on proliferation, migration, invasion and prognosis ([@b33-ijo-53-01-0073]--[@b35-ijo-53-01-0073]). We hypothesized that HOXA1 serves a significant role in NSCLC via the p53 signaling pathway, but the detailed mechanism of HOXA1 in NSCLC requires determining. To test this hypothesis, we plan to apply a variety of approaches, including cell proliferation, migration, invasion and apoptosis assays, and animal models, in future studies. The clinical significance and the molecular mechanism of HOXA1 in the biological function of NSCLC will be investigated at the molecular, cellular, tissue and animal levels. The findings of the present study with regard to HOXA1 provide a novel biomarker or therapeutic target for NSCLC.
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![Clinical significance of HOXA1 in NSCLC based on reverse transcription-quantitative-polymerase chain reaction. Differential expression of HOXA1 in (A) NSCLC and non-cancerous lung tissue; (B) in NSCLC stage I+II vs. III+IV; and (C) in NSCLC with LNM vs. without LNM. (D) ROC curve of HOXA1 in NSCLC. HOXA1, homeobox A1; NSCLC, non-small cell lung cancer; ROC, receiver operating characteristic.](IJO-53-01-0073-g00){#f1-ijo-53-01-0073}

![Clinical significance of HOXA1 in LUAD and LUSC based on reverse transcription-quantitative-polymerase chain reaction. Differential expression of HOXA1 (A) in LUSC and non-cancerous lung tissue; (B) in LUAD stage I+II vs. III+IV; (C) in LUAD with LNM vs. without LNM; (D) in LUSC stage I+II vs. III+IV; and (E) in LUSC with LNM vs. without LNM. (F) ROC curve of HOXA1 in LUAD. (G) ROC curve of HOXA1 in LUSC. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; HOXA1, homeobox A1; ROC, receiver operating characteristic.](IJO-53-01-0073-g01){#f2-ijo-53-01-0073}

![Clinical significance of HOXA1 in LUAD and LUSC based on The Cancer Genome Atlas database. Differential expression of HOXA1 in (A) LUAD and non-cancerous lung tissue; and (B) in LUSC and non-cancerous lung tissue. (C) ROC curve of HOXA1 in LUAD. (D) ROC curve of HOXA1 in LUSC. (E) Kaplan-Meier curves of HOXA1 expression in LUAD. Patients with high HOXA1 expression had a significantly poorer prognosis (75.15±9.68 months) compared with those with low expression (97.11±11.49 months). (F) Kaplan-Meier curves of HOXA1 expression in LUSC. Patients with high HOXA1 expression had a significantly better prognosis (71.05±4.81 months) compared with those with low expression (66.79±6.53 months). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; HOXA1, homeobox A1; ROC, receiver operating characteristic.](IJO-53-01-0073-g02){#f3-ijo-53-01-0073}

![Validation of HOXA1 expression based on the Oncomine and GEPIA databases for representative examples. (A) Normal lung tissues (n=19) and LUAD tissues (n=20) were included in the cohort of Stearman Lung based on the Oncomine database. (B) Normal lung tissues (n=5) and LUSC tissues (n=5) were included in the cohort of Wachi Lung based on the Oncomine database. (C) Normal lung tissues (n=347) and LUAD tissues (n=483) were included based on the GEPIA database. (D) Normal lung tissues (n=338) and LUSC tissues (n=486) were included based on the GEPIA database. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; HOXA1, homeobox A1; GEPIA, Gene Expression Profiling Interactive Analysis; T, tumor tissues; N, normal lung tissues.](IJO-53-01-0073-g03){#f4-ijo-53-01-0073}

![Venn diagrams for the genes co-expressed with homeobox A1. Based on GEPIA, TCGA and MEM databases, 1,264 co-expressed genes were found. GEPIA, Gene Expression Profiling Interactive Analysis; TGCA, The Cancer Genome Atlas; MEM, Multi Experiment Matrix.](IJO-53-01-0073-g04){#f5-ijo-53-01-0073}

![A functional network of GO terms for the genes co-expressed with homeobox A1 in non-small cell lung cancer. GO analysis was performed using the overlapping genes, and a functional network was constructed to further reflect the functions of these genes. GO, Gene Ontology.](IJO-53-01-0073-g05){#f6-ijo-53-01-0073}

![PPI network of the co-expressed genes. The PPI network was constructed via the Search Tool for the Retrieval of Interacting Genes online, and 908 PPI pairs with a connectivity degree of \>30 were chosen for further analysis. PPI, protein-protein interaction.](IJO-53-01-0073-g06){#f7-ijo-53-01-0073}

![Differential expression of CDKN2A and CHEK1 in LUAD and LUSC based on The Cancer Genome Atlas database. (A) Differential expression of CDKN2A between LUAD and normal lung tissue. (B) Differential expression of CHEK1 between LUAD and normal lung tissue. (C) Differential expression of CDKN2A between LUSC and normal lung tissue. (D) Differential expression of CHEK1 between LUSC and normal lung tissue. CDKN2A, cyclin-dependent kinase inhibitor 2A; CHEK1, checkpoint kinase 1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](IJO-53-01-0073-g07){#f8-ijo-53-01-0073}

![Differential expression of miRNAs in LUAD and LUSC based on The Cancer Genome Atlas database. (A) Differential expression of miR-181b between LUAD and non-cancerous lung tissue. (B) Differential expression of miR-28 between LUAD and non-cancerous lung tissue. (C) Differential expression of miR-181d between LUAD and non-cancerous lung tissue. (D) Differential expression of miR-181b between LUSC and non-cancerous lung tissue. (E) Differential expression of miR-28 between LUSC and non-cancerous lung tissue. (F) Differential expression of miR-181d between LUSC and non-cancerous lung tissue. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; miR/miRNA, microRNA.](IJO-53-01-0073-g08){#f9-ijo-53-01-0073}

###### 

Expression of HOXA1 and correlations with clinicopathological parameters in NSCLC based on reverse transcription-quantitative polymerase chain reaction.

  Clinicopathological-features   n    HOXA1 expression (2^−∆∆Cq^)                                                         
  ------------------------------ ---- ----------------------------- ----------------------------------------------------- ---------
  Tissues                                                                                                                 
   Normal lung                   53   1.00                          2.589                                                 0.011
   NSCLC                         53   1.57                                                                                
  Pathology                                                                                                               
   LUAD                          31   1.30                          −1.714                                                0.096
   LUSC                          22   1.91                                                                                
  Size, cm                                                                                                                
   ≤3                            15   1.22                          −1.679                                                0.100
   \>3                           38   1.70                                                                                
  TNM                                                                                                                     
   I--II                         29   1                             −4.366                                                \<0.001
   III--IV                       24   2.26                                                                                
  Sex                                                                                                                     
   Male                          40   1.57                          −0.154                                                0.878
   Female                        13   1.61                                                                                
  Age, years                                                                                                              
   \<60                          33   1.70                          1.193                                                 0.238
   ≥60                           20   1.30                                                                                
  Smoking                                                                                                                 
   No                            29   1.61                          0.271                                                 0.787
   Yes                           24   1.52                                                                                
  Vascular invasion                                                                                                       
   No                            48   1.52                          −0.620                                                0.538
   Yes                           5    1.87                                                                                
  LNM                                                                                                                     
   No                            28   1                             −4.323                                                \<0.001
   Yes                           25   2.22                                                                                
  Grade                                                                                                                   
   I                             5    1.43                          0.154[a](#tfn1-ijo-53-01-0073){ref-type="table-fn"}   0.858
   II                            38   1.60                                                                                
   III                           10   1.39                                                                                

F-value. NSCLC, non-small cell lung cancer; HOXA1, homeobox A1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TNM, TNM, Tumor-Node-Metastasis; LNM, lymph node metastasis.

###### 

Expression of HOXA1 and associations with clinicopathological parameters in LUAD based on reverse transcription-quantitative polymerase chain reaction.

  Clinicopathological-features   n    HOXA1 expression (2^−∆∆Cq^)                                                         
  ------------------------------ ---- ----------------------------- ----------------------------------------------------- -------
  Tissues                                                                                                                 
   Normal lung                   53   1.00                          1.387                                                 0.169
   LUAD                          31   1.291                                                                               
  Size, cm                                                                                                                
   ≤3                            9    1.090                         −0.795                                                0.433
   \>3                           22   1.372                                                                               
  TNM                                                                                                                     
   I--II                         19   1.026                         −2.236                                                0.033
   III--IV                       12   1.709                                                                               
  Sex                                                                                                                     
   Male                          23   1.214                         −0.812                                                0.423
   Female                        8    1.509                                                                               
  Age, years                                                                                                              
   \<60                          19   1.444                         1.221                                                 0.232
   ≥60                           12   1.047                                                                               
  Smoking                                                                                                                 
   No                            17   1.440                         1.033                                                 0.310
   Yes                           14   1.111                                                                               
  Vascular invasion                                                                                                       
   No                            29   1.300                         0.176                                                 0.861
   Yes                           2    1.184                                                                               
  LNM                                                                                                                     
   No                            18   0.991                         0.279                                                 0.024
   Yes                           13   1.705                                                                               
  Grade                                                                                                                   
   I                             5    1.406                         0.318[a](#tfn2-ijo-53-01-0073){ref-type="table-fn"}   0.730
   II                            23   1.316                                                                               
   III                           3    0.906                                                                               

F-value. HOXA1, homeobox A1; LUAD, lung adenocarcinoma; TNM, TNM, Tumor-Node-Metastasis; LNM, lymph node metastasis.

###### 

Expression of HOXA1 and associations with clinicopathological parameters in LUSC based on reverse transcription-quantitative polymerase chain reaction.

  Clinicopathological-features   n    HOXA1 expression (2^−∆∆Cq^)            
  ------------------------------ ---- ----------------------------- -------- -------
  Tissues                                                                    
   Normal lung                   53   1.00                          −2.666   0.012
   LUSC                          22   1.872                                  
  Size, cm                                                                   
   ≤3                            6    1.342                         −1.087   0.290
   \>3                           16   2.073                                  
  TNM                                                                        
   I--II                         10   0.863                         −4.009   0.001
   III--IV                       12   2.714                                  
  Sex                                                                        
   Male                          17   1.932                         0.341    0.736
   Female                        5    1.679                                  
  Age, years                                                                 
   \<60                          14   2.000                         0.547    0.591
   ≥60                           8    1.654                                  
  Smoking                                                                    
   No                            12   1.761                         −0.404   0.690
   Yes                           10   2.009                                  
  Vascular invasion                                                          
   No                            19   1.809                         −0.525   0.605
   Yes                           3    2.278                                  
  LNM                                                                        
   No                            10   0.936                         −3.535   0.002
   Yes                           12   2.654                                  
  Grade                                                                      
   I                             0    --                            0.417    0.526
   II                            15   1.407                                  
   III                           7    1.585                                  

HOXA1, homeobox A1; LUSC, lung squamous cell carcinoma; TNM, TNM, Tumor-Node-Metastasis; LNM, lymph node metastasis.

###### 

Expression of HOXA1 and associations with clinico-pathological parameters in LUAD based on The Cancer Genome Atlas.

  Clinicopathological features   n[a](#tfn4-ijo-53-01-0073){ref-type="table-fn"}   HOXA1 expression                                                         
  ------------------------------ ------------------------------------------------- ------------------ ----------------------------------------------------- -------
  Tissues                                                                                                                                                   
   Normal lung                   59                                                4.308±0.087        3.153                                                 0.002
   LUAD                          535                                               5.079±0.081                                                              
  Age, years                                                                                                                                                
   \<60                          136                                               5.268±1.922        1.037                                                 0.300
   ≥60                           357                                               4.52±2.419                                                               
  Sex                                                                                                                                                       
   Male                          236                                               5.092±1.951        −0.326                                                0.745
   Female                        276                                               5.146±1.789                                                              
  Ethnicity                                                                                                                                                 
   White                         387                                               5.128±1.898        0.656[b](#tfn5-ijo-53-01-0073){ref-type="table-fn"}   0.519
   Black                         52                                                5.011±1.963                                                              
   Asian                         7                                                 4.341±1.475                                                              
  T                                                                                                                                                         
   T1+T2                         444                                               5.118±1.842        0.036                                                 0.971
   T3+T4                         65                                                5.110±2.024                                                              
  N                                                                                                                                                         
   NX                            11                                                5.459±1.481        2.970[b](#tfn5-ijo-53-01-0073){ref-type="table-fn"}   0.052
   N0--N1                        425                                               5.034±1.809                                                              
   N2--N3                        75                                                5.583±2.150                                                              
  M                                                                                                                                                         
   MX                            140                                               5.061±1.819        0.541[b](#tfn5-ijo-53-01-0073){ref-type="table-fn"}   0.582
   M0                            343                                               5.170±1.865                                                              
   M1                            25                                                4.809±2.087                                                              
  Stage                                                                                                                                                     
   I+II                          395                                               5.053±1.791        −1.765                                                0.078
   III+IV                        109                                               5.410±2.112                                                              

Total number of patients is not always 535, as the clinical data of certain subgroups was missing.

F-value. HOXA1, homeobox A1; LUAD, lung adenocarcinoma; T, umor; N, node; M, metastasis; SD, standard deviation.

###### 

Expression of HOXA1 and associations with clinico-pathological parameters in LUSC based on The Cancer Genome Atlas.

  Clinicopathological features   n[a](#tfn6-ijo-53-01-0073){ref-type="table-fn"}   HOXA1 expression                                                         
  ------------------------------ ------------------------------------------------- ------------------ ----------------------------------------------------- ---------
  Tissues                                                                                                                                                   
   Normal lung                   49                                                4.942±0.652        −25.988                                               \<0.001
   LUSC                          502                                               7.774±1.268                                                              
  Ethnicity                                                                                                                                                 
   White                         349                                               7.776±1.289        1.751[b](#tfn7-ijo-53-01-0073){ref-type="table-fn"}   0.175
   Asian                         9                                                 7.120±1.692                                                              
   Black                         30                                                8.031±1.163                                                              
  Age, years                                                                                                                                                
   ≥60                           213                                               7.798±1.247        0.403                                                 0.688
   \<60                          44                                                7.711±1.585                                                              
  Sex                                                                                                                                                       
   Male                          371                                               7.833±1.199        1.759                                                 0.079
   Female                        130                                               7.606±1.438                                                              
  Stage                                                                                                                                                     
   I--II                         406                                               7.780±1.244        0.419                                                 0.675
   III--IV                       91                                                7.718±1.392                                                              
  T                                                                                                                                                         
   T1--T2                        407                                               7.817±1.211        1.593                                                 0.112
   T3--T4                        94                                                7.586±1.481                                                              
  N                                                                                                                                                         
   N0--N1                        450                                               7.761±1.273        0.390[b](#tfn7-ijo-53-01-0073){ref-type="table-fn"}   0.677
   N2--N3                        45                                                7.925±1.155                                                              
   NX                            6                                                 7.611±1.760                                                              
  M                                                                                                                                                         
   M0                            411                                               7.765±1.237        0.013[b](#tfn7-ijo-53-01-0073){ref-type="table-fn"}   0.986
   M1                            5                                                 7.837±1.034                                                              
   MX                            79                                                7.783±1.475                                                              

Total number of patients is not always 502, as the clinical data of certain subgroups was missing.

F-value. HOXA1, homeobox A1; LUSC, lung squamous cell carcinoma; T, tumor; N, node; M, metastasis; SD, standard deviation.

###### 

Top 10 enriched GO terms (BP, CC, and MF) of the genes co-expressed with homeobox A1.

  GO ID        Term                                                                                           Ontology   Count   Fold enrichment   P-value
  ------------ ---------------------------------------------------------------------------------------------- ---------- ------- ----------------- ----------
  GO:0002159   Desmosome assembly                                                                             BP         3       11.270307         0.024213
  GO:0046070   dGTP metabolic process                                                                         BP         3       11.270307         0.024213
  GO:0015014   Heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process   BP         3       11.270307         0.024213
  GO:0002934   Desmosome organization                                                                         BP         7       10.518953         0.000014
  GO:0002138   Retinoic acid biosynthetic process                                                             BP         4       10.018050         0.005034
  GO:0003150   Muscular septum morphogenesis                                                                  BP         4       10.018050         0.005034
  GO:0046602   Regulation of mitotic centrosome separation                                                    BP         3       9.016245          0.038591
  GO:0009217   Purine deoxyribonucleoside triphosphate catabolic process                                      BP         3       9.016245          0.038591
  GO:1901490   Regulation of lymphangiogenesis                                                                BP         3       9.016245          0.038591
  GO:0002568   Somatic diversification of T cell receptor genes                                               BP         3       9.016245          0.038591
  GO:0000942   Condensed nuclear chromosome outer kinetochore                                                 CC         3       10.830268         0.026117
  GO:0035985   Senescence-associated heterochromatin focus                                                    CC         3       10.830268         0.026117
  GO:0005587   Collagen type IV trimer                                                                        CC         4       9.626905          0.005634
  GO:0098642   Network-forming collagen trimer                                                                CC         4       8.251633          0.009355
  GO:0098645   Collagen network                                                                               CC         4       8.251633          0.009355
  GO:0098651   Basement membrane collagen trimer                                                              CC         4       7.220179          0.014205
  GO:0031616   Spindle pole centrosome                                                                        CC         4       5.776143          0.027431
  GO:0000778   Condensed nuclear chromosome kinetochore                                                       CC         4       5.251039          0.035817
  GO:0000940   Condensed chromosome outer kinetochore                                                         CC         4       4.813453          0.045359
  GO:0030057   Desmosome                                                                                      CC         8       4.620915          0.001182
  GO:0019834   Phospholipase A2 inhibitor activity                                                            MF         3       11.38088          0.023761
  GO:0019237   Centromeric DNA binding                                                                        MF         4       8.671148          0.008147
  GO:0004859   Phospholipase inhibitor activity                                                               MF         7       8.17089           0.000092
  GO:0086083   Cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication    MF         3       7.587255          0.054384
  GO:0004064   Arylesterase activity                                                                          MF         3       7.587255          0.054384
  GO:0017002   Activin-activated receptor activity                                                            MF         3       6.503361          0.072879
  GO:0003696   Satellite DNA binding                                                                          MF         3       6.503361          0.072879
  GO:0045294   α-catenin binding                                                                              MF         4       6.069804          0.024071
  GO:0016595   Glutamate binding                                                                              MF         4       6.069804          0.024071
  GO:0055102   Lipase inhibitor activity                                                                      MF         7       5.901198          0.000749

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Top 10 KEGG pathway enrichment results of the genes co-expressed with homeobox A1.

  KEGG ID    KEGG term                    Count   Fold enrichment   P-value
  ---------- ---------------------------- ------- ----------------- ----------
  hsa04115   p53 signaling pathway        17      3.803218          0.000005
  hsa04520   Adherens junction            16      3.377838          0.000051
  hsa04512   ECM-receptor interaction     19      3.273493          0.000012
  hsa03430   Mismatch repair              5       3.258512          0.062662
  hsa05222   Small cell lung cancer       17      2.997831          0.000125
  hsa04666   FcγR-mediated phagocytosis   16      2.855077          0.000369
  hsa04110   Cell cycle                   22      2.659366          0.000059
  hsa04350   TGF-β signaling pathway      14      2.498192          0.003421
  hsa04330   Notch signaling pathway      8       2.498192          0.038016
  hsa05217   Basal cell carcinoma         9       2.452771          0.027883

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Correlations between homeobox A1 and three miRNAs (miR-181b, miR-28 and miR-181d) in non-small cell lung cancer based on The Cancer Genome Atlas.

  Cancer type   r        P-value
  ------------- -------- ---------
  LUAD                   
   miR-181b     −0.104   0.018
   miR-28       −0.010   0.827
   miR-181d     −0.158   \<0.001
  LUSC                   
   miR-181b     −0.205   \<0.001
   miR-28       0.057    0.216
   miR-181d     −0.106   0.020

LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; miR/miRNA, microRNA.
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